ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

Shares of ImmunityBio, Inc. (IBRX) drew investor focus in pre-market trading on Monday after the pharmaceutical firm reported better-than-expected fourth-quarter results.

Net product revenue for Q4 surged 431% to $38.3 million, above Wall Street’s estimates of $37.8 million, according to Fiscal.ai data. ImmunityBio cited the increase in revenue to the sales of ANKTIVA, a U.S. Food and Drug Administration (FDA) approved immunotherapy for bladder and lung cancer.

However, Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&D expense, the company said. R&D expense for the quarter increased by $28.7 million to $63.9 million.

The stock gained 5% with IBRX among the top trending tickers on Stocktwits at the time of writing.

Get updates to this developing story on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<